[HTML][HTML] Development of virus-specific CD4+ T cells during primary cytomegalovirus infection

RJ Rentenaar, LE Gamadia… - The Journal of …, 2000 - Am Soc Clin Investig
RJ Rentenaar, LE Gamadia, FNJ van Diepen, R Boom, JFL Weel, PME Wertheim-van Dillen…
The Journal of clinical investigation, 2000Am Soc Clin Investig
Although virus-specific CD4+ T cells have been characterized extensively in latently infected
individuals, it is unclear how these protective T-cell responses develop during primary virus
infection in humans. Here, we analyzed the kinetics and characteristics of cytomegalovirus-
specific (CMV-specific) CD4+ T cells in the course of primary CMV infection in kidney
transplant recipients. Our data reveal that, as the first sign of specific immunity, circulating
CMV-specific CD4+ T cells become detectable with a median of 7 days after first …
Although virus-specific CD4+ T cells have been characterized extensively in latently infected individuals, it is unclear how these protective T-cell responses develop during primary virus infection in humans. Here, we analyzed the kinetics and characteristics of cytomegalovirus-specific (CMV-specific) CD4+ T cells in the course of primary CMV infection in kidney transplant recipients. Our data reveal that, as the first sign of specific immunity, circulating CMV-specific CD4+ T cells become detectable with a median of 7 days after first appearance of CMV-DNA in peripheral blood. These cells produce the T helper 1 type (Th1) cytokines IFNγ and TNFα, but not the T helper 2 type (Th2) cytokine IL4. In primary CMV infection, the vast majority of these circulating virus-specific T cells have features of recently activated naive T cells in that they coexpress CD45RA and CD45R0 and appear to be in the cell cycle. In contrast, in people who have recovered from CMV infection earlier in life, virus-specific T cells do not cycle and express surface markers characteristic of memory T cells. After the initial rise, circulating virus-specific CD4+ T cells decline rapidly. During this phase, a strong rise in IgM and IgG anti-CMV antibody titers occurs, concomitant with the reduction of CMV-DNA in the circulation.
The Journal of Clinical Investigation